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Co-enzyme Q10 (Co-Q10) is an essential component of the mitochondrial electron transport chain. Most cells are
sensitive to co-enzyme Q10 (Co-Q10) deficiency. This deficiency has been implicated in several clinical disorders
such as heart failure, hypertension, Parkinson’s disease and obesity. The lipid lowering drug statin inhibits conversion
of HMG-CoA to mevalonate and lowers plasma Co-Q10 concentrations. However, supplementation with Co-Q10
improves the pathophysiological condition of statin therapy. Recent evidence suggests that Co-Q10 supplementation
may be useful for the treatment of obesity, oxidative stress and the inflammatory process in metabolic
syndrome. The anti-inflammatory response and lipid metabolizing effect of Co-Q10 is probably mediated by
transcriptional regulation of inflammation and lipid metabolism. This paper reviews the evidence showing beneficial
role of Co-Q10 supplementation and its potential mechanism of action on contributing factors of metabolic and
cardiovascular complications.
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Metabolic syndrome is a cluster of disease symptoms
such as dyslipidemia, hyperglycemia and insulin resist-
ance, hypertension and visceral obesity [1]. Oxidative
stress and inflammation are pivotal in all stages of athero-
sclerosis, hypertension, and non-alcoholic fatty liver and
in subjects with metabolic syndrome [2,3]. Mitochondrial
dysfunction plays a crucial role in the development of dia-
betes and metabolic disorder [4]. Both, animal and clinical
studies revealed that the sources of free radicals would be
from mitochondrial origin [4]. The mitochondrial electron
transport chain is the generator of free radicals mainly
singlet oxygen (O.-) while producing the ATP from the
substrate molecule. Free radicals may react with other
important molecules within cells and enhance lipid
peroxidation, oxidize proteins and damage DNA and are
thus responsible for oxidative stress [2]. Inflammatory re-
sponses are also responsible for most of the organ dys-
function in metabolic disorder. Increased concentration* Correspondence: sonaliagun@yahoo.com
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article, unless otherwise stated.and expression of tumor necrosis factor-α (TNF-α),
interleukin-6 (IL-6), and monocyte chemoattractant
protein-1 (MCP-1) are evident in adipocyte dysfunction
and insulin resistance in obesity and metabolic syndrome
[5]. Furthermore, inflammatory cells infiltration are also
increased in adipose tissues which is responsible for adi-
pocyte dysfunction [6]. Inflammation in adipose tissues
could be a causative factor diminishing mitochondrial bio-
genesis and energy homoeostasis [7-9]. Therefore, sup-
plementation with a dietary antioxidant having anti-
inflammatory properties would be beneficial which can
scavenge free radicals and restores antioxidant defence
as well as suppresses inflammatory responses. Co-enzyme
Q10 (Co-Q10), an integral part of the mitochondrial elec-
tron transport chain which transports electrons and acts
as a natural antioxidant (Figure 1). Co-Q10 can also be
found in much of the human diet. Beneficial effects of Co-
Q10 supplementation have been noted for most of the
symptoms of metabolic syndrome, e.g. hypertension, dia-
betes, liver diseases, insulin resistance and obesity. This
review will thus, focus on the effect of Co-Q10 on various
component of metabolic syndrome and elucidate its po-
tential mechanism of action.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Schematic diagram of Co-Q10, Mito-Q and Idebenone.
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Chemically Co-Q10 is a quinone molecule found almost
in all cells of the body, hence the term ubiquinones [10].
It exists in nature and in the body, ubiquinones, the oxi-
dized form and ubiquinol, the reduced form. Co-Q10
serves as an essential carrier for the electron transfer in
the mitochondrial respiratory chain for the synthesis of
ATP. Co-Q10 was first isolated in 1957 from beef mito-
chondria [10]. Folkers et al. revealed the chemical struc-
ture of Co-Q10 in 1958 [11]. Meat, poultry and fish are
the richest sources of Co-Q10, and the daily intake of
these foods provides between 3 to 5 mg of Co-Q10
[12,13]. The absorption of Co-Q10 from the diet occurs
mainly in the small intestine and is better absorbed in
presence of lipid rich foods [14]. Co-Q10 is then trans-
ported to the liver and form lipoprotein complex and
deposited in tissues [14]. Tissues with high-energy re-
quirements and metabolic rates such as the heart and
the skeletal muscle contain relatively high concentra-
tions of Co-Q10 [15]. About 95% of Co-Q10 in human
circulatory system exists in its reduced form as ubiquinol
[16]. The safety of high doses of orally-ingested Co-Q10
over long periods is well documented in human [17] and
also in animals [18]. Co-Q10 dosages generally range from
100 to 200 mg a day for patients suffering cardiovascular
disease [19].
Mitochondrial biogenesis and Co-Q10
Mitochondrial biogenesis means the increased number
and function of mitochondria due to the response of in-
creased cellular energy demand and thereby increased
ATP production. Generally, mitochondrial electron trans-
port chain consists of several protein complexes, namely,
complex I, complex II, complex III and complex IV etc.
[20]. NADH which donates electrons to complex I and
FADH2 feed the electron to complex II. Glucose oxidation
through glycolysis and pyruvate dehydrogenase to acetylCoA generates NADH. In contrast, fatty acid oxidation to
acetyl-CoA generates FADH2 through the process of β-
oxidation. Acetyl CoA from both sources feeds the TCA
cycle. Electrons coming from NADH and FADH2 are thus
transported via reduced Co-Q10 to Complex III [20]. The
proton gradient is generated as a consequence of this se-
quential process, drives complex V or the ATPase to pro-
duce ATP. ATP is thus transported via ANP to its target
site. In presence of uncoupling agent, the protomotive force
will divert to UCPs and a proton leak occurs. Thus the en-
ergy will expend as heat without producing any ATP. Com-
plex I and complex III are the primary sources of O2 free
radicals due to incomplete reduction of the oxygen
molecule. The Mitochondrial environment maintains a
highly protective defence against this free radical. In
normal physiological conditions these free radicals are
scavenged by superoxide dismutase of mitochondrial
origin and later by catalase in cytosol. Diabetic hyper-
glycemia and metabolic disorder are responsible for
the inactivity of these antioxidant enzyme systems and
decreased mitochondrial function. Several evidences
suggest that, inhibition of the mitochondrial electron
transport chain activity may increase lipid accumula-
tion in adipocyte [21,22].
Mitochondrial biogenesis can be modulated by several
transcriptional regulators present in the cell. Peroxisome
proliferator activated receptor (PPAR) family is such a
regulator of mitochondrial biogenesis [23]. Three types
of PPAR proteins have been identified so far, PPAR-α,
PPAR-γ and PPAR-δ [24]. PPARs activation is also im-
portant for lipid metabolism, adipocyte differentiation
and the prevention of inflammation [24]. Moreover,
PPARs also regulate mitochondrial biogenesis via an ac-
tivator called peroxisome proliferator-activated receptor
gamma coactivator-1α (PGC-1α) [25,26]. PGC-1α is
physiologically regulated by exercise [27,28] and calorie
restriction [29]. Apart from these exercise and calorie
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fibrates [30] and resveratrol [31] stimulate PGC-1α and
restore mitochondrial function. Co-Q10 mediated acti-
vation of PPARs are revealed only recently which would
be a possible mechanism of energy homeostasis in failing
tissues and obesity [32].
Metabolic disorder due to Co-Q10 deficiency
Ogashara et al. described the first patients (two sisters) with
primary Co-Q10 deficiency in 1989 [33]. They had pro-
gressive muscle weakness, abnormal fatigue, and central
nervous system dysfunction from early childhood charac-
terized by a low Co-Q10 concentration in their muscles.
Both patients improved remarkably with oral Co-Q10
[33]. Maintaining adequate Co-Q10 level throughout the
body is important for normal function and health. Plasma
concentrations of Co-Q10 are high in healthy infant and
children and declining with age [34,35]. Metabolic dis-
order may arise due to Co-Q10 deficiency. Growing
bodies of evidences indicate that oxidative stress plays a
critical role in the pathogenesis of type 2 diabetes mellitus
and its complications [36]. Low plasma Co-Q10 concen-
trations were found in patients with poor glycaemic con-
trol and diabetic complications [37-40].
HMG-CoA reductase inhibitors (statins) reduce Co-
Q10 levels in human [41,42]. Alternatively, supplemen-
tation with oral Co-Q10 can restore plasma Co-Q10
levels in patients receiving statin therapy [41-43]. Sta-
tin mediated Co-Q10 depletion affects muscle func-
tion. Patients taking statin to reduce plasma lipids
suffered myalgia and myopathic pain [44-46]. Myocar-
dial depletion of Co-Q10 has also been demonstrated
in heart failure patients with cardiomyopathy which
was improved by Co-Q10 therapy [47]. An important
factor contributing to statin related myopathy may be a
genetic susceptibility to muscle disorders and underlying
metabolic mechanisms [48,49]. Due to the statin therapy,
genomic variation has been found in COQ2 gene which
encoding para-hydroxybenzoate-polyprenyl transferase for
CoQ10 biosynthesis [48]. Another report suggests that
statins may affect energy metabolism (Carnitine palmitoyl-
transferase II deficiency) combined with a genetic suscep-
tibility triggering myopathic outcomes in certain high-risk
patients [49].
Antioxidant effect of Co-Q10
Benzoquinone group of Co-Q10 is able to accept and
donate electrons which is a critical feature for an anti-
oxidant [14]. It scavenges free radicals and inhibits lipid
and protein peroxidation. Vitamin E and Co-Q10 pre-
vents lipid peroxidation at nearly the same rate [50].
However, Co-Q10 prevents LDL oxidation more effi-
ciently than α-tocopherol, lycopene, or β-carotene
[51]. Co-Q10 also enhances the availability of otherantioxidants such as vitamin C, vitamin E and beta-
carotene [52]. Direct elimination of free radical such as
lipid peroxyl, peroxyl and/or alkoxyl radicals in vitro and
in vivo as a consequence of Co-Q10 supplementation was
reported by several investigators [53,54]. Co-Q10 may also
serve as an antioxidant by acting as a cofactor and activa-
tor of mitochondrial uncoupling proteins, leading to a re-
duction in free radical generation in vivo [55]. H2O2-
induced DNA strand breaks in lymphocytes are protected
by ubiquinol-10 [56]. In another study, in vivo supplemen-
tation with Co-Q10 was shown to enhance the recovery of
human lymphocytes from oxidative DNA damage [57].
Improved cellular antioxidant enzyme activity was also
noted for Co-Q10 supplementation. Co-Q10 treatment in-
creased antioxidant enzyme activity of superoxide dismut-
ase, catalase, and glutathione in the liver homogenates of
diabetic rats followed by reduced lipid peroxidation [58].
Antioxidant enzyme, catalase activity and GSH concentra-
tion were also improved in liver of acetaminophen in-
duced rats [59]. A recent clinical study also showed that
Co-Q10 supplementation at a dose of 150 mg decreased
oxidative stress and improved antioxidant enzyme activ-
ity in patients with coronary artery disease [60].
Effect of Co-Q10 on inflammation and metabolic syndrome
Inflammation is a response to tissue or organ damage
from exogenous and endogenous factors and assists in
the restoration of impaired homeostasis. Several inflam-
matory cytokine are also generated e.g. interleukin-1 (IL-
1), interleukin-6 (IL 6), tumour necrosis factor- α (TNF-α)
etc. which have both systemic and local effect. Local ef-
fects are associated with increased expression of adhesion
cell molecules such as intracellular adhesion molecule-1
(ICAM-1), selectins and heat-shock proteins [61]. Macro-
phage infiltration and fibroblast activation are two inflam-
matory responses develop chronically in inflamed adipose
tissues [6,62]. Systemic chronic inflammatory response is
also considered to be a mediator of metabolic syndrome
and insulin resistance [62,63]. Pro-inflammatory cytokines
and oxidative stress have been shown to be responsible for
developing metabolic disturbances, such as insulin resist-
ance and activation of immune response in liver, adipose
tissue and in muscle [64-66]. Moreover, activation of in-
flammatory pathways in hepatocytes is sufficient to cause
both local as well as systemic insulin resistance [67,68].
Recent studies have confirmed positive association be-
tween obesity indices and inflammatory markers, mainly
c-reactive protein (CRP) and other inflammatory cyto-
kines [69-71]. Evidence is also starting to accumulate that
inflammatory cytokines are over expressed in adipose tis-
sues of obese rodent models and obese humans [72-75].
Some other studies suggest that systemic administration
of the TNF-α also induces insulin resistance in experimen-
tal animal [76,77]. In recent years, several inflammatory
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kinase (JNK) pathways, protein kinase-C (PKC) and IκB
kinase (IKK) mediated nuclear factor- κB (NF-κB) path-
ways and suppressor of cytokine signaling (SOCS) family
mediated pathways [63]. Furthermore, PKC and IKK can
be activated by increased fatty acid level in cells [63].
Low density lipoprotein (LDL) cholesterol oxidation is
the key regulator for developing inflammation in endothe-
lial cells and other tissues [78]. The LDL receptor plays a
vital role in increasing uptake of cholesterol from plasma to
cell and increasing clearance of apoB and apoE-containing
lipoproteins [79]. In diabetes and obesity, LDL-R popula-
tions decrease and increase LDL level in plasma [80].
LDLR−/− mice showed an increased plasma lipid profile
and an increase in inflammatory markers in response to
high fat diet [79,81,82]. The anti-atherogenic effect of
PPARγ agonist was seen in LDLR−/− male mice which is
correlated with improved insulin sensitivity and decreased
tissue expression of TNF-α and gelatinase B [83]. However,
peroxisome proliferator activated receptor-γ (PPAR-γ) is re-
ported to attenuate inflammation in activated macrophages
by interfering with NF-κB signalling [84]. PPAR-α is an-
other analogue of the PPAR family also regulates anti-
inflammatory genes (Figure 2) [85].Figure 2 Proposed mechanism of Co-Q supplementation on anti-infla
metabolic syndrome. AMPK, Adenosine monophosphate activated protei
Peroxisome proliferator-activated receptor gamma coactivator-1; oxLDL, Ox
Liver X receptor; PPRE PPAR response element.The anti-inflammatory activity of Co-Q10 is well doc-
umented. Stimulation of cells with LPS resulted in a distinct
release of TNF-α, macrophage inflammatory protein-1
alpha (MIP-1α) and monocyte chemo attractant protein-1
(MCP-1) which were significantly attenuated by pre-
incubation of cells with the reduced form of Co-Q10
[86,87]. Treatment with CoQ10 also reduced the elevated
plasma lipid profiles and decreased mRNA expression of
the pro-inflammatory cytokine TNF-α in adipose tissues
of ob/ob mice [88]. CoQ10 supplementation also im-
proved the inflammatory state in liver of high fat fructose
diet fed rats [89]. Recent evidence suggests that Co-Q10
can serve as an agonist of PPARs and activates the PPAR
mediated anti-inflammatory response (Figure 2) [90,91].
Effect of Co-Q10 on endothelial dysfunction
and hypertension
Endothelial dysfunction and hypertension are common in
metabolic syndrome. Increased glucose intolerance and
oxidative stress plays a critical role in the development of
endothelial dysfunction in aortas of diabetic rats [36]. Co-
Q10 supplementation improved the endothelial dysfunc-
tion in the mesenteric arteries in high fat diet fed SHRsp
rats [92]. Inflammatory cell infiltration may be a potentialmmatory and lipid metabolism pathways in tissues in case of
n kinase; PPAR, Peroxisome proliferator activated receptor; PGC-1α,
idized Low density lipoprotein; NRF, nuclear respiration factor; LXR,
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aortas. Co-Q10 prevented the lymphocytic infiltration
in perivascular area of aortas from fructose fed rats [93].
Co-Q10 also improved endothelial dysfunction in statin-
treated type II diabetic patients [94]. Considerable evidence
indicates that oxLDL-induced endothelial dysfunction is as-
sociated with down-regulation of eNOS and up-regulation
of inducible nitric oxide synthase (iNOS). A recent
study showed that Co-Q10 prevented apoptosis in human
umbilical vein endothelial cells (HUVEC) due to oxLDL
by preventing the NF-kB mediated caspase-3 activation
[95]. Co-Q10 also attenuated the oxLDL-mediated down-
regulation of endothelial nitric oxide synthase (eNOS)
and up-regulation of inducible nitric oxide synthase
(iNOS) [95]. oxLDL induced inflammatory process
and expression of adhesion molecules, release of pro-
inflammatory cytokines and the adherence of monocyte
were also attenuated by CoQ10 in THP-1 cells [95].
Extracellular superoxide dismutase (ecSOD) activity and
endothelium-dependent vasodilatation were also im-
proved remarkably after CoQ10 supplementation which
alters local vascular oxidative stress [96].
The antihypertensive effect of Co-Q10 is also well docu-
mented in animal and human studies. Co-Q10 supple-
mentation reduced hypertension and cardiac hypertrophy
in DOCA-salt hypertensive rats [97,98]. The Co-Q10
analogue decylubiquinone (10 mg/kg) reduced the systolic
blood pressure, plasma malondialdehyde, total cholesterol
and LDL-cholesterol in the SHRsp rats [99]. A recent
meta-analysis of clinical trials investigating the use of Co-
Q10 for treatment of hypertension considered 12 trials
since 1975 and found beneficial effect of Co-Q10 supple-
mentation [100]. Among these trials, four were prospect-
ive randomized trials and eight trials considering the
effect of Co-Q10 on final blood pressure compared with
previous level [100]. Co-Q10 supplementation has
shown to be effective in lowering blood pressure in dia-
betes, improves the glycaemia control in metabolic syn-
drome; however, a recent study showed that Co-Q10
treatment failed to reduce blood pressure in patients with
uncontrolled hypertension [101]. Another study suggests
that treatment with Co-Q10 (50 mg twice a day for ten
weeks) in patients with essential hypertension reduced
hypertension without affecting the plasma renin activity,
serum and urinary sodium and potassium, and urinary
aldosterone [102]. These results suggest that treatment
with Co-Q10 decreases blood pressure in patients with
essential hypertension, possibly because of a reduction
in peripheral resistance [102]. However, the exact mech-
anism is not known, but one theory proposed that it re-
duces peripheral resistance by preserving nitric oxide
bioavailability [103]. Alternatively, coenzyme Q10 may
increase the synthesis and sensitivity of prostacyclin
(PGI2), a potent vasodilator and inhibitor of plateletaggregation, to arterial smooth muscle and does relax-
ation to arteries [104].
Effect of Co-Q10 on cardiac dysfunction
Clinically, Co-Q10 has potential for the prevention and
treatment of cardiovascular diseases such as myocardial
infarction, congestive heart failure and other drug- in-
duced/disease induced cardiomyopathies [105]. The
heart is highly sensitive to Co-Q10 deficiency. Defective
levels of specific oxidative phosphorylation/respiratory en-
zyme activities and reduced energy reserve in heart failure
may be considered as contributing factors for the progres-
sion of disease [106]. Low levels of Co-Q10 concentration
were found in 70–75% of patients with aortic stenosis or
insufficiency, mitral stenosis or insufficiency, diabetic car-
diomyopathy, atrial septal defects and ventricular septal
defects [107]. Circulating levels of Co-Q10 were also sig-
nificantly lower in patients with ischemic heart disease
and in patients with dilated cardiomyopathy as compared
to healthy controls [108]. Pepe et al. have reviewed the
meta analysis of clinical trials of Co-Q10 in heart failure,
reporting that cardiac output, cardiac index and stroke
volumes were improved with the treatment of Co-Q10
[103]. Diastolic dysfunction is one of the earliest identifi-
able signs of myocardial failure due to severe thickening
of the left ventricles, which accounts for 30-49% of heart
failure cases. Patients treated with 200 mg/day of Co-Q10
improved interventricular septal thickness significantly
with improved symptoms of fatigue and dyspnea with no
side effects noted [109]. Studies on isolated rat’s heart also
demonstrated a protective effect of Co-Q10 against ische-
mia and reperfusion injuries [110,111]. Pre-treatment with
Co-Q10 improved recovery of cardiac function, aerobic ef-
ficiency and enzyme levels in young healthy rats compared
to untreated controls undergone experimentally induced
ischemia-reperfusion in heart [112]. In an another study,
mice pre-treated with Co-Q10 for 4 days prior to toxic
doses of adriamycin, survival rates were significantly
higher (80%) compared to the mice not received the sup-
plements (40%) [113]. This Co-Q10 mediated protection
against adriamycin induced cardiac toxicities is probably
due to the inhibition of lipid peroxidation and induction
antioxidant enzymes in cardiac tissue [114].
Effect of Co-Q10 on diabetes and insulin resistance
Coenzyme Q concentrations appear to be reduced in
diabetic states. Diabetic animals showed decreased Co-
Q10 concentration in heart, liver and skeletal muscle
[115]. Evidence also exists for reduced Co-Q in plasma
of humans with diabetes. Lower plasma levels of CoQH2
have been found in diabetic patients than healthy sub-
jects [37,116]. Supplementation with Co-Q10 would be
beneficial for diabetes and insulin resistance. Co-Q10
supplementation (10 mg/kg) improved the elevated
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induced diabetic rats without affecting the insulin con-
centration [58]. However, 200 mg of Co-Q10 daily for
6 months did not improve glycemic control or serum
lipid levels of Type-2 diabetics [117]. In another random-
ized double-blind, placebo-controlled study, Co-Q10 sup-
plementation at a dose 100 mg for three months failed to
improve HbA1c, mean daily blood glucose concentrations,
mean insulin dose, number of hypoglycemic episodes or
cholesterol concentrations compared to the placebo group
[118]. Improved glycemic control due to Co-Q10 supple-
mentation could be a protective action against pancreatic
beta cell destruction in diabetes. Co-Q10 supplementation
did not reduce the pancreatic damage, inflammation and
beta cell loss in diabetic rats but decrease glycated HbA1c
and pancreatic lipid peroxidation [119]. Further researches
are required to evaluate the hypoglycaemic action of Co-
Q10 supplementation.
Liver steatosis and effect of Co-Q10 on hepatic
dysfunction
Oxidative stress and inflammatory responses are respon-
sible for hepatic damage and fibrosis. The liver X recep-
tors (LXR) constitute a class of nuclear receptors activated
by oxidized lipids (Figure 2). Activation of LXR in macro-
phages induces expression of several genes involved in
lipid metabolism and reverse cholesterol transport [120].
Activation of these transcription factors inhibits inflam-
matory gene expression in macrophages and adipocytes,
largely through PPAR-γ mediated suppression of NF-κB
signalling [121,122]. LXR also plays an important role in
lipid and cholesterol metabolism. LXRα knockout mice
develop enlarged fatty livers, degeneration of liver cells,
high cholesterol levels in liver, and impaired liver function
when fed a high-cholesterol diet [123]. Generally, oxidized
LDL serves as an agonist of LXR and modulates PPAR
binding to DNA sequence elements termed peroxisome
proliferator response elements (PPRE) [124]. Thus, an-
tioxidants such as Co-Q10 may prevent LDL oxidation
and serve as an LXR antagonist. Recent report showed
that reduced form of Co-Q10 downregulated genes in-
volved in cholesterol biosynthesis (HMGCS1, HMGCL
and HMGCR) which are also deactivated by transcrip-
tional regulators PPARα and LXR/RXR complex in liver
of SAMP1 mice [125]. However, oxidized form of Co-Q10
did not alter the genes expression of HMGCS1, HMGCL
and HMGCR [91,125]. A recent report also suggests that
LXRs influence CoQ synthesis without directly regulating
the process and CO-Q10 concentration was found to be
decreased in liver of LXR-α knockout mice and LXR
double knockout mice [126].
A high fat diet and fructose feeding can also cause
dyslipidemia and hepatic steatosis. Co-Q10 supplemen-
tation increases life-span of rats fed a diet enriched withpolyunsaturated fatty acids [127,128]. High fat diet in-
duced hepatic oxidative stress in rats was improved by
supplementation with Co-Q10 followed by the improve-
ment of the plasma lipid profile [89]. The lipid lowering
effect of Co-Q10 supplementation was also seen in fruc-
tose fed rats [93]. A Co-Q10 analogue, Q monomethyl
ether, also showed beneficial effect on progressive non-
alcoholic fatty liver (NAFL) in rats fed a high fat diet and
improved liver architecture by preventing the fat droplet
accumulation in hepatocytes [129]. Increased fatty acid
beta oxidation would be the potential mechanism of
improving lipid profile in metabolic syndrome. Scanty lit-
erature was found on any effect of Co-Q10 on mitochon-
drial fatty acid beta oxidation. However, up regulation of
the beta oxidation gene was observed in animal treated
with ubiquinol [90]. Recent evidence suggests that this
up-regulation of fatty acid oxidation is probably involved
PPAR mediated pathways [90]. It is now evident that ubi-
quinol, a reduced form of Co-Q10, may be an activator of
PPAR gene expression and activated a series of lipid me-
tabolizing gene family in mice [90,91]. Alternatively,
ubiquinol downregulated a series of genes involved in
cholesterol and fatty acid synthesis such as HMGCS1,
HMGCL and HMGCR [91]. These genes are also nega-
tively regulated by PPAR mediated pathways.
Co-Q10 supplementation also showed hepatic protec-
tion in other model of hepatic dysfunction. Co-Q10 treat-
ment showed hepatic protection against acetaminophen
induced liver toxicities in rats [59]. Co-enzyme Q10
treatment improved extensive centrilobular necrosis,
cytoplasmic vacuolization and ballooning degeneration
of hepatocytes with congested sinusoids in liver of rats
[59]. Hepatic protection in these rats depends on the
blocking NF-kB mediated inflammatory signal pathways
and inactivation of caspase activity [59]. Co-Q10 sup-
plementation is also effective in preventing the toxin in-
duced hepatic damage [130]. Co-Q10 supplementation
in diet also showed hepatic protection in aged rats due
to enhanced cellular antioxidant action [131].
Effect of Co-Q10 on obesity and fat metabolism
Generally, obese individuals showed a reduction of fat
metabolism and increased fat deposition in the body. In-
creased fat deposition is responsible for the hypergly-
cemia, insulin resistance, dyslipidemia and hypertension,
most of the common features of metabolic syndrome
[132]. Mitochondrial dysfunction and reduced Co-Q10
concentration was found in obese individual [133]. Adi-
pocyte differentiation and fat deposition into adipocytes
play important roles in obesity. Co-Q10 prevents adipogen-
esis in rosiglitazone induced adipogenesis in ob/ob mice
[88]. Anti-adipogenic activity of Co-Q10 was also shown in
3 T3-F442A cell line. Inhibition of Co-Q10 synthesis
strongly triggered adipocyte differentiation while increment
Table 1 Effect of Co-Q10 supplementation on lipid metabolism in metabolic syndrome
Parameter Model and dose Effect and potential mechanism Reference
Lipid metabolism
3 T3-L1 pre-adipocytes
-Increases fatty acid beta oxidation. [32]
- ↑ Ca++ Influx; ↑AMPK; ↑PPAR-α.
-Prevents adipocytes differentiation
Fructose fed rat -↓Total cholesterol; ↓LDL-Cholesterol; ↓triglycerides [93]
ob/ob mice
- ↓ Total cholesterol; ↓triglycerides; ↓NEFA [88]
- ↓ mRNA expression of the lipogenic enzymes such as fatty
acid synthase (FAS) and acetyl-CoA carboxylase 1 (ACC1).
C57BL6J mice - Increases fatty acid beta oxidation [90]
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ation [134]. Co-Q10 treatment increases fat oxidation and
energy expenditure in inguinal white adipose tissue. De-
creased mRNA expression of the lipogenic enzymes fatty
acid synthase (FAS) and acetyl-CoA carboxylase 1 (ACC1),
and the glycerogenic enzyme phosphoenolpyruvate carbox-
ykinase (PEPCK) are responsible for the lipid lowering ef-
fect of Co-Q10 [88]. In this study, mRNA expression of
proteins involved in mitochondrial biogenesis (peroxisome
proliferator-activated receptor-g coactivator-1 (PGC-1)),
oxidative phosphorylation system (OXPHOS) system (cyto-
chrome oxidase subunit IV (COIV)), fatty acid transport
into mitochondria (carnitine-palmitoyl transferase 1,
muscle isoform (M-CPT1)) and energy expenditure (un-
coupling protein-1 (UCP1)) were also increased to promote
the fatty acid utilization in high fat diet fed mice [88].
AMPK regulates the expression of lipogenic genes, includ-
ing fatty acid synthesis (FAS) [135]. Co-Q10 increased the
AMPK phosphorylation in 3 T3-L1preadipocytes probably
by increasing the cytoplasmic calcium concentrations
followed by increased Ca2+/calmodulin-dependent pro-
tein kinase kinase (CaMKK). Moreover, Co-Q10 in-
creased fatty acid oxidation in 3 T3-L1preadipocytes
and increased PPARα in protein and mRNA level [32].
This AMPK-mediated PPARα induction at least in part
causes suppression of adipocyte differentiation [32].
Future perspectives and conclusion
Co-Q10 has proven potential as an antioxidant molecule
with anti-inflammatory properties. Recent evidence also
suggests that Co-Q10 may serve as AMPK and PPARs
activators and increases the fat burning capacity of cells
(Table 1). Its use is still limited due to poor water solu-
bility and lipophilic nature. Several analogues have so far
been synthesized such as mito-Q and idebenone.
Mito-Q10 comprises a lipophilic triphenylphosphonium
cation covalently attached to an ubiquinol antioxidant
[136]. The lipophilic triphenylphosphonium cation helps
this molecule to easily cross the lipid bilayer, be orally bio-
available and accumulate in mitochondria several hundred
fold compared with Co-Q10 itself [136]. MitoQ10 has beenshown to be effective against mitochondrial oxidative dam-
age in vivo and in rodent models of sepsis and reperfusion
injury of heart [137,138]. Administration of MitoQ10 also
protects against the development of hypertension, im-
proves endothelial function, and reduces cardiac hyper-
trophy in young stroke-prone spontaneously hypertensive
rats [139]. MitoQ, was shown to completely prevent mito-
chondrial abnormalities as well as cardiac dysfunction
characterized by a diastolic dysfunction [140]. Recent
evidence suggests that Mito-Q is effective against etha-
nol induced micro and macro hepatic steatosis in rats
[141]. Metabolic dysfunctions were also improved in mice
treated with Mito-Q. Mito-Q supplementation reduced
the fat mass and plasma lipid profile in ApoE−/− mice
[142]. MitoQ supplementation also improved hypergly-
cemia, hepatic steatosis and decreased DNA oxidative
damage (8-oxo-G) in multiple organs of ApoE−/− mice
[142]. Idebenone, a benzoquinone carrying exactly the
same quinone moiety as Co-Q0, Co-Q1 and Co-Q10,
shows multiple activities in vitro and in vivo. Idebenone
is quickly absorbed and is well tolerated and safe given
as single or repeated daily doses [143]. Like Co-Q10,
idebenone also prevents lipid peroxidation and ROS
production in vivo [144-146]. However, to date, no more
literature has been found with an idebenone effect on
diabetes and metabolic syndrome. In view of the above
discussion, Co-Q10 supplementation has proven its ef-
ficacy and benefit to treat metabolic syndrome and
obesity. Further research is warranted to get benefit in a
clinical setup.Abbreviations
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